chufangao/CTO huggingface dataset:
Clinical trial NCT02296541: Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults
Official title: A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of 3 Different HIV-1 DNA Priming Regimens (Nat-B Env, CON-S Env, and Mosaic Env) With MVA-CMDR Boosts in Healthy, HIV-1-Uninfected Adults
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 105.0 (ACTUAL)
Number of arms: 6.0
Start date: 2014-12-31
Primary completion date: 2016-11-30
Completion date: 2020-07-06
Clinical trial NCT05057897: A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults
Official title: A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19
Acronym: VICTORIA
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Removal of the commitment for Immune compromised study (D81111C00010) due to recruitment challenges.
Enrollment: 34.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-01-31
Primary completion date: 2023-04-19
Completion date: 2023-04-19
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT05153148: A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
Official title: A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 305.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-01-06
Primary completion date: 2023-05-04
Completion date: 2023-06-02
Baseline population: Full Analysis Set included all randomized participants who received at least one dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04079803: PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Official title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients
Sponsor: Cassava Sciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 64.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-09
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT03799198: Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity
Official title: Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity - a Pragmatic Randomized Trial
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 200.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-07
Primary completion date: 2020-05-22
Completion date: 2020-05-22
Baseline population: Full analysis set (FAS) comprised of all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT04326439: AflacLL1901 (CHOA-AML)
Official title: CHOA-AML: A Pilot Study for Newly Diagnosed Pediatric Patients With Acute Myeloid Leukemia (AML)
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial; thus, it was terminated.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-24
Primary completion date: 2022-03-15
Completion date: 2022-03-15
Plan to share individual participant data: NO
Clinical trial NCT04257656: A Trial of Remdesivir in Adults With Severe COVID-19
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.
Sponsor: Capital Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The epidemic of COVID-19 has been controlled well in China, no eligible patients can be enrolled at present.
Enrollment: 237.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-06
Primary completion date: 2020-03-30
Completion date: 2020-04-10
Plan to share individual participant data: UNDECIDED
Clinical trial NCT06326138: Pharmacokinetics and Pharmacodynamics of Edoxaban Before and After Bariatric Surgery
Official title: Pharmacokinetics and Pharmacodynamics of Edoxaban in Subjects With Severe Obesity Before and After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass
Acronym: EXPOSE
Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No support form the sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-03-11
Primary completion date: 2024-03-11
Completion date: 2024-03-11
Plan to share individual participant data: NO
Clinical trial NCT05001854: Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients
Official title: Evaluation of the Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline in Septic Shock Patients
Acronym: FLUDROSEPSIS
Sponsor: Rennes University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: SUSPENDED 
Why stopped: study suspended until new therapeutic units are available
Enrollment: 40.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2022-03-31
Primary completion date: 2024-06-30
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT02149823: Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Official title: Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: All study proceedings stopped prematurely due to Covid-19 restrictions for intranasal formulations
Enrollment: 92.0 (ACTUAL)
Number of arms: 5.0
Start date: 2013-09-30
Primary completion date: 2020-07-31
Completion date: 2022-06-14
Clinical trial NCT04723186: MT1002 Phase II Study in ACS Patients With PCI
Official title: Open-Label, Sequential-Dose Escalation/De-escalation Trial Testing MT1002 in Patients Undergoing PCI Due to Acute Coronary Syndrome With NSTEMI
Sponsor: Shaanxi Micot Technology Limited Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was decided to be terminated due to commercial considerations,（not the safety issues of the product）.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-02
Primary completion date: 2023-08-31
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT04448756: Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
Official title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)
Sponsor: EMD Serono (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 149.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-07-29
Primary completion date: 2021-08-16
Completion date: 2021-08-16
Baseline population: Safety analysis set included all participants who had received at least one dose of study intervention.
Plan to share individual participant data: YES
IPD sharing description: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
IPD time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union
IPD access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.
Clinical trial NCT03478163: Antibiotics During Intrauterine Balloon Tamponade Placement
Official title: Antibiotics During Intrauterine Balloon Tamponade Placement
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Problems with recruitment
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-08
Primary completion date: 2021-05-03
Completion date: 2021-05-03
Plan to share individual participant data: NO
Clinical trial NCT01311518: A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
Official title: A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery
Sponsor: RegeneRx Biopharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Trial never initiated
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-31
Primary completion date: 2020-07-31
Completion date: 2020-07-31
Clinical trial NCT04391894: A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
Official title: A Randomized, Double-masked, Multicenter Study to Evaluate the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 558.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-10-06
Primary completion date: 2021-05-13
Completion date: 2021-05-13
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT04311515: To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
Official title: A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
Sponsor: Samus Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Samus Therapeutics company closure
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-30
Primary completion date: 2020-09-09
Completion date: 2022-11-15
Plan to share individual participant data: NO
Clinical trial NCT03287960: Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
Official title: An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
Sponsor: Rhythm Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-30
Primary completion date: 2020-09-25
Completion date: 2020-09-25
Limitations and caveats: Based on meetings with the Federal Drug Administration (FDA), the structure of the endpoints was slightly different in the statistical analysis plan (SAP) and the protocol.~In addition, there was no planned comparison to a randomized placebo group given the rarity of monogenic LEPR deficiency obesity.
Plan to share individual participant data: NO
Clinical trial NCT05181865: Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors
Official title: A Phase 1/2a, First-In-Human, Open Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FL-301 in Patients With Advanced Solid Tumors
Sponsor: Flame Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 8.0
Start date: 2022-01-31
Primary completion date: 2022-01-18
Completion date: 2022-01-18
Clinical trial NCT03266159: A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors
Official title: A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Small Cell Lung Cancer and Ras-Mutated Solid Tumors
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study withdrawn before active to fully evaluate impact of changing practice in target population.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2017-11-27
Primary completion date: 2020-08-19
Completion date: 2020-08-19
Clinical trial NCT02587572: Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial
Official title: A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.
Acronym: SIRONA
Sponsor: Longeveron Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor has made decision not to conduct this clinical trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-12-01
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Clinical trial NCT04875533: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
Official title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 60 YEARS OF AGE AND OLDER IN JAPAN, KOREA, AND TAIWAN
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1425.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-14
Primary completion date: 2022-05-13
Completion date: 2022-05-13
Baseline population: All participants who receive at least 1 dose of the study intervention (20vPnC, 13vPnC, PPSV23 or saline).
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02518191: Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
Official title: Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity in Women With Breast Cancer in China
Sponsor: Shanghai Jiao Tong University Affiliated Sixth People's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 345.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-01
Primary completion date: 2021-01-12
Completion date: 2021-01-12
Plan to share individual participant data: NO
Clinical trial NCT02408016: Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Official title: Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated due to loss of funding
Enrollment: 11.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-05-22
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Baseline population: No patients were treated in Arm II
Clinical trial NCT01844505: Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Official title: A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1296.0 (ACTUAL)
Number of arms: 3.0
Start date: 2013-06-11
Primary completion date: 2016-08-01
Completion date: 2024-04-19
Baseline population: All randomized participants
Clinical trial NCT05760781: To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
Official title: Phase Ib/II: Multicenter, Open, Dose-escalation Evaluation of the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B Treated With Oral Antiviral Therapy
Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited.
Enrollment: 9.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-04-25
Primary completion date: 2023-12-11
Completion date: 2023-12-11
Plan to share individual participant data: NO
Clinical trial NCT04661917: A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.
Official title: A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of BAY 2327949 in Patients With Chronic Kidney Disease (eGFR Range From 25 to 60 mL/Min/1.73 m²) Due to Type 2 Diabetes or Hypertension and at Least One Cardiovascular Comorbidity
Acronym: ASSESS-CKD
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study withdrawn due to company decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-31
Primary completion date: 2022-04-25
Completion date: 2022-05-19
Plan to share individual participant data: UNDECIDED
IPD sharing description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access.~As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT03485976: Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Official title: Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Sponsor: Oregon Health and Science University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-23
Primary completion date: 2019-10-14
Completion date: 2020-01-13
Baseline population: All enrolled patients at baseline
Plan to share individual participant data: NO